<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48554">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474121</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IDE 13996 (CA)</org_study_id>
    <nct_id>NCT02474121</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access</brief_title>
  <acronym>MOBILE-CA</acronym>
  <official_title>MarrOwStim™ PAD Kit for the Treatment of Critical LimB IschemIa (CLI) in Subjects With Severe Peripheral ArteriaL DiseasE (PAD) (MOBILE) - Continued Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <brief_summary>
    <textblock>
      This study will continue to evaluate the performance of the MarrowStim™ PAD Kit to treat
      subjects with critical limb ischemia (CLI) caused by severe PAD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a continued access enrollment intended for subjects with critical limb ischemia
      (CLI) that are unsuitable for revascularization. The investigational treatment utilizes
      autologous concentrated bone marrow aspirate (cBMA) at the point of care. The bone marrow
      aspirate is obtained from the subject's hip, concentrated with a bone marrow concentration
      device, and delivered intramuscularly to the affected limb. Subjects meeting the
      inclusion/exclusion criteria will be treated with the MarrowStim™ PAD Kit and followed for a
      total of five years. Information on subject outcomes, such as the occurrence of amputation
      and death, as well as measurements of rest pain, blood flow (ankle-brachial index,
      toe-brachial index), and quality of life will be collected. Safety information (via adverse
      event reporting) will also be collected.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Critical Limb Ischemia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bone marrow concentration device</intervention_name>
    <description>Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb</description>
    <other_name>MarrowStim™ PAD Kit</other_name>
    <other_name>Bone Marrow Concentrate</other_name>
    <other_name>Bone Marrow Mononuclear Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral or bilateral lower extremity ischemia due to advanced peripheral arterial
             disease

          -  Unsuitable for revascularization

          -  Minor tissue loss (Rutherford Category 5) or ischemic rest pain (Rutherford Category
             4)

          -  Competent to give consent

          -  No current malignancy or history of previous malignancy within the last five years,
             with the exception of adequately treated non-melanoma skin cancer (evidence of
             standard preventative cancer screenings required)

        Exclusion Criteria:

          -  Major tissue loss (Rutherford Category 6)

          -  Diabetics with uncontrolled or untreated proliferative retinopathy

          -  Poorly controlled diabetes mellitus with HbA1C &gt; 10%

          -  Uncompensated congestive heart failure and/or other conditions that preclude general
             anesthesia

          -  Myocardial infarction or stroke within last 90 days

          -  Elevated liver function tests (AST or ALT more than twice the upper limit of normal)

          -  Renal disease (creatinine &gt; 2.5 mg/dl) or chronic hemodialysis

          -  White blood cell count &lt; 3,000/µL or &gt; 15,000/µL, platelet count &lt; 100,000/µL, or
             hematocrit &lt; 32%

          -  Topical growth hormone therapy within last 90 days, or injected growth hormone
             therapy within last 180 days

          -  Disease of central nervous system and/or other conditions that impair cognitive
             function

          -  Two or more episodes of pulmonary embolus with a documented DVT in index leg or
             history of DVT in index leg without evidence of clot resolution

          -  Current infection of index leg

          -  Pregnant women (negative urine pregnancy test required)

          -  Lower extremity venous disease with pitting edema in index leg

          -  Recent history (in the 6 months prior to screening) of bone marrow disease or
             treatment with any medication or procedure which adversely affects the bone marrow
             and would prohibit transplantation

          -  Current osteomyelitis in index leg

          -  Existing HIV diagnosis

          -  Organ transplant recipients

          -  Known terminal disease process with life expectancy less than one year

          -  Severe concomitant disease(s) or any additional condition(s) which the investigator
             feels constitute(s) criteria for exclusion of a particular subject

          -  Major amputation required within 30 days

          -  Inclusion in any other clinical study that may affect the outcome of this study

          -  Uncorrected stenosis(es) of greater than 50% in the common and/or external iliac
             artery and/or common femoral artery of the index leg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Hillary Overholser</last_name>
    <phone>574-371-1087</phone>
    <email>hillary.overholser@zimmerbiomet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Arkansas Veterans Healthcare System</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandi Brock</last_name>
      <phone>501-257-6906</phone>
      <email>brocksandraj@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed Moursi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California-Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christy Pifer</last_name>
      <phone>916-734-4156</phone>
      <email>capifer@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>John Laird, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shan Liu</last_name>
      <phone>404-605-4098</phone>
      <email>Shan.Liu@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Charles Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristen Wanczyk</last_name>
      <phone>317-988-9548</phone>
      <email>keevans@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Erica Tangney</last_name>
      <phone>617-636-8404</phone>
      <email>etangney@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Mark Iafrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marion Cyriac, MD</last_name>
      <phone>201-530-7967</phone>
      <email>m-cyriac@mail.holyname.org</email>
    </contact>
    <investigator>
      <last_name>John Rundback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anusha Jayaram</last_name>
      <phone>212-241-8250</phone>
      <email>anusha.jayaram@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Ageliki Vouyouka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Carrick</last_name>
      <phone>412-360-3653</phone>
      <email>jennifer.carrick@va.gov</email>
    </contact>
    <investigator>
      <last_name>Edith Tzeng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bevin Lopez</last_name>
      <phone>713-441-6537</phone>
      <email>balopez@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Eric Peden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robyn McKenzie</last_name>
      <phone>434-982-1058</phone>
      <email>rrm5f@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Aditya Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murphy MP, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, Hutchins GD, March KL. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg. 2011 Jun;53(6):1565-74.e1. doi: 10.1016/j.jvs.2011.01.074. Epub 2011 Apr 22.</citation>
    <PMID>21514773</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>June 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
